Publication

Method for determining cancer invasiveness and patient prognosis

Douglas Hanahan, Leanne Li
2019
Patents

Abstract

A method for determining the prognosis for survival of a patient having cancer is disclosed, said cancer being altered (i.e. highly activated or alternatively inactive/inhibited) in the NMDAR signalling pathway, said method comprising determining the expression levels of a plurality of gene products in a sample from a cancer patient relative to a control, wherein the differential expression of said plurality of gene products relative to a control is indicative of cancer aggressiveness and of the patient's prognosis. A method for improving the prognosis for a cancer patient being diagnosed to have a poor prognosis, as well as pharmaceutical compositions for that purpose, are also disclosed, said method comprising modulating the level or the activity of the identified gene products and/or a member of the NMDA signalling pathways and/or a DLGAP family gene products and/or a HSF1 gene product and/or a FMR1 gene product.

Official source

https://infoscience.epfl.ch/entities/publication/76505aca-0bcc-4f6a-8b2d-8a10f0ca60ae

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Douglas Hanahan, Leanne Li
2019
Patents

Abstract

Official source

https://infoscience.epfl.ch/entities/publication/76505aca-0bcc-4f6a-8b2d-8a10f0ca60ae

About this result

Ontological neighbourhood

Biology

Cell biology: Cancer

Related concepts (32)

Treatment of cancer

Cancer can be treated by surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy (including immunotherapy such as monoclonal antibody therapy) and synthetic lethality, most commonly as a series of separate treatments (e.g. chemotherapy before surgery). The choice of therapy depends upon the location and grade of the tumor and the stage of the disease, as well as the general state of the patient (performance status). Cancer genome sequencing helps in determining which cancer the patient exactly has for determining the best therapy for the cancer.

Cancer

Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. These contrast with benign tumors, which do not spread. Possible signs and symptoms include a lump, abnormal bleeding, prolonged cough, unexplained weight loss, and a change in bowel movements. While these symptoms may indicate cancer, they can also have other causes. Over 100 types of cancers affect humans. Tobacco use is the cause of about 22% of cancer deaths.

Colorectal cancer

Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, is the development of cancer from the colon or rectum (parts of the large intestine). Signs and symptoms may include blood in the stool, a change in bowel movements, weight loss, and fatigue. Most colorectal cancers are due to old age and lifestyle factors, with only a small number of cases due to underlying genetic disorders. Risk factors include diet, obesity, smoking, and lack of physical activity.

Related publications (31)

Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy

Ali Ghasemi

Dendritic cells (DCs) are specialized myeloid cells with the ability to uptake, process, and present antigens to T lymphocytes. They also generate cytokine and chemokine gradients that regulate immune cell trafficking, activation, and function. Monocyte-de ...

EPFL2024

6-diazo-5-oxo-l-norleucine prodrugs

Xile Hu, Li Tang, Céline Jasmin Prange

The present invention relates to 6-diazo-5-oxo-L-norleucine prodrugs having reduced toxicity and increased tumor specificity and to their therapeutic use for treating cancer. ...

2024

NMR and MS reveal characteristic metabolome atlas and optimize esophageal squamous cell carcinoma early detection

Lijing Xin, Yan Lin, Wei Ye, Yubo Zhao

Metabolic changes precede malignant histology. However, it remains unclear whether detectable characteristic metabolome exists in esophageal squamous cell carcinoma (ESCC) tissues and biofluids for early diagnosis. Here, we conduct NMR- and MS-based metabo ...

Nature Portfolio2024